In humans, hereditary cerebellar ataxias develop gradually resulting from the degeneration of cerebellar neurons and their afferent and efferent connections. The long term goal of this investigation is to see whether insulin-like growth factor I (IGF-1) can rescue cerebellar neurons from dying in cerebeltar mutant mice, thereby evaluating the therapeutic potential of IGF-l in treating cerebellar ataxia in humans. IGF-l is an anabolic growth factor required for optimal neuronal proliferation, differentiation and survival. IGF-l's neurotropic effect is best illustrated during the development of the cerebellum, where IGF-l and its receptor genes are normally expressed coordinately with the postnatal cerebellar growth spurt. When cerebellar growth is affected by gene mutations (wv and pcd mice), IGF-l's biological activity usually decreases before ataxia occurs, suggesting that normal IGF-l levels are pivotal for the functional integrity of cerebellar cytoarchitecture. On the other hand, IGF-l transgenic mice have bigger brains with more myelin and more brain cells. Among all brain regions, the cerebellum is affected most. It is twice the normal size, containing 92 percent more granule cells and 20 percent more Purkinje cells than are found in wild type littermates. To fully evaluate the therapeutic potential of IGF-l in the treatment of cerebellar ataxia, this investigation will: 1. characterize the cellular mechanism of IGF-l's neuroprotection for cerebellar neurons; 2. cross breed IGF-l transgenic mice with wv and pcd mutant mice and examine the resulting histology, molecular biology and behavior changes in IGF-I transgenic mice that contain zero, one or two wv or pcd alleles; and 3. evaluate the therapeutic effects of IGF-l delivered by microencapsulated mammalian cells engineered to synthesize and release IGF-l upon stimulation. The results of this investigation will provide crucial information about the therapeutic potential of IGF-I in treating hereditary cerebellar ataxia.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-BDCN-5 (01))
Program Officer
Gwinn, Katrina
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Indiana University-Purdue University at Indianapolis
Schools of Medicine
United States
Zip Code
Yao, Weiguo; Zhong, Jin; Yu, Jun et al. (2008) IGF-I improved bone mineral density and body composition of weaver mutant mice. Growth Horm IGF Res 18:517-25
Yao, Weiguo; Bethin, Kathleen; Yang, Xianlin et al. (2007) Role of the GH/IGF-I axis in the growth retardation of weaver mice. Endocrine 32:227-34
Zhong, Jin; Deng, Jixian; Phan, Jennifer et al. (2005) Insulin-like growth factor-I protects granule neurons from apoptosis and improves ataxia in weaver mice. J Neurosci Res 80:481-90
Zhong, Jin; Deng, Jixian; Huang, Su et al. (2004) High K+ and IGF-1 protect cerebellar granule neurons via distinct signaling pathways. J Neurosci Res 75:794-806
Zhong, Jin; Deng, Jixian; Ghetti, Bernardino et al. (2002) Inhibition of insulin-like growth factor I activity contributes to the premature apoptosis of cerebellar granule neuron in weaver mutant mice: in vitro analysis. J Neurosci Res 70:36-45